Tech Company Financing Transactions
Augmenix Funding Round
Catalyst Health Ventures, Excelestar Ventures and Sparta participated in a $10.8 million Series D funding round for Augmenix. The financing round was announced on 7/24/2014.
Transaction Overview
Company Name
Announced On
7/24/2014
Transaction Type
Venture Equity
Amount
$10,800,000
Round
Series D
Proceeds Purpose
These funds are anticipated to see Augmenix through to SpaceOAR System approval and US market launch, with commercialization activities expected to commence in earnest in 2015.
Company Information
Company Status
Acquired or Merged
Industry
Medical Devices & Instruments
Mailing Address
204 2nd Ave. Lower Level
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Augmenix's hydrogel technology improves outcomes in prostate radiation oncology and surgery. Learn more about the SpaceOAR system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Pedersen
President
Pat Campbell
VP - Operations
Nick Svencer
VP - Regulatory Affairs
Noel Rolon
VP - Sales
Ken Knudson
Browse more venture capital transactions:
Prev: 7/23/2014: Antengo venture capital transaction
Next: 7/24/2014: LoopPay venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs